Pomerantz Announces Notice of Dismissal of Astex

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pomerantz Announces Notice of Dismissal of Astex Pharmaceuticals, Inc. Class Action and Agreement to Pay Attorneys' Fees and Expenses

NEW YORK, Nov. 11, 2014 (GLOBE NEWSWIRE) -- By order of the Delaware Court of Chancery dated November 5, 2014, the following notice is being published. Former stockholders of Astex Pharmaceuticals, Inc. (ASTX) are urged to review the following notice.

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

IN RE ASTEX PHARMACEUTICALS, INC. )   CONSOLIDATED

STOCKHOLDERS LITIGATION                  )      C.A. No. 8917-VCL

NOTICE OF DISMISSAL OF CLASS ACTION AND AGREEMENT
TO PAY ATTORNEYS FEES AND EXPENSES

TO:   All Persons who held shares of Astex Pharmaceuticals, Inc. at any time during the period from and including September 5, 2013 through October 11, 2013.

The purpose of this Notice is to inform you about developments with respect to the above-captioned action (the "Action"), including the benefits conferred on Astex Pharmaceuticals, Inc. ("Astex") stockholders in connection therewith, the dismissal of the above-captioned consolidated class action (the "Consolidated Action"), an agreement to pay attorneys' fees and expenses to counsel for Plaintiffs in the Consolidated Action, and your right to object to that fee agreement prior to the closure for all purposes of the Consolidated Action.

By way of background, plaintiffs commenced the Consolidated Action on behalf of themselves and a putative class of Astex stockholders to challenge a series of transactions set forth in a September 5, 2013 merger agreement between Astex and Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), pursuant to which Otsuka ultimately acquired, through a tender offer (the "Tender Offer"), all outstanding shares of Astex for $8.50 per share in cash (the "Transaction").

Related actions were commenced by other Astex stockholders in state court in California (the "California Actions") to challenge the Transaction on behalf of a similar putative class of Astex stockholders (which were consolidated under Wagner v. Astex Pharmaceuticals, Inc. , Case No. HG13695090 (Alameda Cnty. Sup. Ct. Sept. 17, 2013)).

On September 13, 2013, Astex issued an initial Schedule 14D-9 Solicitation/Recommendation Statement (the "14D-9") that, among other things, described the background of the Transaction, the fairness opinion issued in connection with the Transaction, and certain financial projections generated by Astex's management.

Plaintiffs in the Consolidated Action and the plaintiffs in the California Actions separately reviewed the 14D-9 and separately filed amended complaints that identified various items that plaintiffs contended should have been, but were not, disclosed to Astex's stockholders in the 14D-9, thus allegedly depriving Astex's stockholders of the ability to make an informed decision whether (i) to tender their shares in support of the Transaction, or (ii) exercise their appraisal rights.

Plaintiffs in the Consolidated Action and plaintiffs in the California Actions reached an agreement to coordinate their efforts in prosecuting the litigation arising out of the Transaction.

Prior to the expiration of the Tender Offer, plaintiffs in the Consolidated Action and plaintiffs in the California Actions engaged in joint expedited discovery pursuant to which Astex and defendants James S.J. Manuso, Charles J. Casamento, Thomas V. Girardi, Allan R. Goldberg, Walter J. Lack, Harren Jhoti, Peter Fellner, Timothy Haines, and Ismail Kola (collectively, the "Astex Defendants") produced more than 50,000 pages of documents concerning, among other things, the process leading up to the Transaction, the financial analyses performed by Astex's financial advisor, Astex's internal financial projections, and details of its potential pipeline of pharmaceutical products throughout its R&D and commercialization process.

The plaintiffs in the Consolidated Action and in the California Actions demanded, among other things, that Astex make certain supplemental disclosures concerning the Transaction, including with respect to the sales process leading up to the Transaction, the financial analyses supporting the fairness opinion provided in support of the Transaction, and, most notably, product-level information concerning Astex's financial projections.

On October 1, 2013, Astex issued a supplemental Schedule 14D-9/A Solicitation/Recommendation Statement (the "Supplemental 14D-9/A"), (accessible on Astex's website at http://www.astx.com , on the website of the U.S. Securities and Exchange Commission 1 , or by contacting Plaintiffs' Delaware Counsel by writing to the address listed below or by phone at (302) 295-5310) which included the additional disclosures regarding the Transaction identified above, and which plaintiffs in the Consolidated Action and in the California Actions believe enabled Astex's stockholders to make a more fully informed decision with respect to the Transaction.

The Transaction closed on October 11, 2013. Also on October 11, 2013, Otsuka filed a motion and brief in support of judgment on the pleadings and a Motion for Class Certification in the Consolidated Action. On October 17, 2013, Astex and the individual defendants filed a motion and brief in support of judgment on the pleadings in the Consolidated Action, and followed up by filing a similar motion, as well as a renewed motion to stay, in the California Actions.

By an Order dated November 1, 2013, the Delaware Court of Chancery (the "Court") certified a class of Astex stockholders (the "Class" as defined in that Order) and appointed lead plaintiffs and lead counsel in the Consolidated Action.

Through their review of the documents and discussions with their financial experts, plaintiffs in the Consolidated Action and in the California Actions jointly concluded that the claims asserted in the Consolidated Action and the California Actions, for which plaintiffs were primarily seeking equitable relief, were either moot due to the supplemental disclosures in the Supplemental 14D-9/A or did not have merit. As such, Plaintiffs decided not to respond to the Defendants motions for judgment on the pleadings. On November 27, 2013, the parties in both the Consolidated Action and the California Actions submitted stipulations to dismiss their respective actions with prejudice as to the named plaintiffs only and without prejudice as to the remaining members of the Class.  The parties did not discuss fees at this time.

On November 29, 2013, the Court granted the Stipulation filed in the Consolidated Action and thereby dismissed the Consolidated Action with prejudice as to the named plaintiffs in the Consolidated Action but without prejudice as to any claims belonging to the remaining members of the Class, and retained jurisdiction solely for the purpose of determining plaintiffs' application for an award of attorneys' fees and reimbursement of expenses. On December 10, 2013, a similar order was entered in the California Actions pursuant to the Stipulation filed therewith, granting the parties' request to dismiss the California Actions with prejudice as to the named plaintiffs but without prejudice as to any claims belonging to the remaining members of the Class. 

Only after the Consolidated Action and the California Actions were dismissed did the parties commence and engage in discussions to resolve issues regarding plaintiffs' counsel's application for fees and expenses and the amount thereof, based on the benefits provided by the supplemental disclosures made on October 1, 2013.

After negotiations, defendants have agreed to make a global fee and expense payment to counsel in both the Consolidated Action and the California Actions in the amount of $640,000.00 in total in recognition of the benefit conferred on Company stockholders through the issuance of the Supplemental 14D-9/A, as detailed above, and to resolve any application for an award of attorneys' fees and expenses to be made by counsel for plaintiffs in the Consolidated Action or the California Actions. Plaintiffs intend to seek an order closing the Consolidated Action (the "Closure Order") after the expiration of the objection period (detailed below) (the "Objection Process").

RIGHT TO OBJECT

If you are a Class member, you may object to the payment of attorneys' fees and expenses described above. Every objection must be in writing and contain: (i) your name, address, email address, and telephone number; (ii) the number of shares of Astex stock you held prior to the consummation of the Transaction, together with third-party documentary evidence, such as the most recent account statement, showing such share ownership; and (iii) a detailed statement of your objections and all grounds therefore, including any supporting documents to be considered by the Court. Written objections must be received within 45 days of the date of this Notice or NO LATER THAN December 26, 2014. All such objections must identify the case number (C.A. No. 8917-VCL) and must be filed with the Court at:

Register in Chancery
500 N. King St. #1551
Wilmington, DE 19801

And copies of all such papers must also be sent to the following Counsel in the Consolidated Action:

RIGRODSKY & LONG, P.A. SEITZ ROSS ARONSTAM & MORITZ LLP
Seth D. Rigrodsky  Collins J. Seitz, Jr.   
Brian D. Long Bradley R. Aronstam 
Gina M. Serra Eric D. Selden 
2 Righter Parkway, Suite 120 100 S. West Street, Suite 400
Wilmington, Delaware 19803 Wilmington, Delaware 19801
Plaintiffs' Delaware Counsel Counsel for Defendants James S.J. Manuso, Harren Jhoti, Charles J. Casamento, Peter Fellner, Thomas V. Girardi, Ismail Kola, Allan R. Goldberg, Timothy Haines, Walter J. Lack, and Astex Pharmaceuticals, Inc.
   
SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP  
Edward B. Micheletti   
Jenness E. Parker  
One Rodney Square  
P.O. Box 636  
Wilmington, Delaware 19899  
   
Attorneys for Defendants Otsuka Pharmaceutical Co., Ltd. and Autumn Acquisition Corporation  

If an objection is filed, and served, in conformity with the procedures outlined in this Notice, a hearing will be held before the Court, in the New Castle County Courthouse, 500 North King Street, Wilmington, Delaware 19801, on Thursday, January 8, 2015, at 2:00 p.m.

If you do not take the steps described above (or if you make objections and those objections are rejected by the Court), you will be bound by the Closure Order which the Court may enter without further action by the parties or other stockholders following the expiration of the objection period.

1   http://www.sec.gov/Archives/edgar/data/919722...c14d9a.htm

Robert S. Willoughby Pomerantz LLP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DigiKey’s Arduino Webinar Puts Edge AI Hardware to Work

Updated Category News Views 34

A Small Board With a Big Practical Question Edge AI is finally getting dragged out of the slide deck and onto the workbench, which is where it ought to prove itself. DigiKey plans to host a free 60-minute webinar on Dec. 2, 2026, at 10 a.m. CST covering Arduino’s new VENTUNO Q edge AI computer. The session promises a hardware tour, an Arduino App Lab walkthrough, and a...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 31

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 67

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 47

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 46

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 0

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 32

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 311

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 131

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 106

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading

Top 5 Most Recently Viewed Articles

Big Lots Adjusts Strategy Amid Bankruptcy Process Challenges

Updated Category News Views 183

Big Lots Updates on Court-Supervised Process No Longer Anticipates Closing Previously Announced Sale to Nexus Capital Management Continues Efforts Towards a Going Concern Transaction Gearing Up for Going Out of Business Sales at Remaining Locations Big Lots, Inc. has recently made crucial updates regarding its financial restructuring efforts. The company has announced...

Continue Reading
Detailed Overview of Man Group PLC's Stake in American Axle

Updated Category News Views 133

Key Information About Man Group PLC's Disclosures FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE This document represents a disclosure by a person with interests in relevant securities, specifically when owning 1% or more of American Axle & Manufacturing Holdings, Inc. As per Rule 8.3 of the Takeover Code, certain details regarding the interests and...

Continue Reading
Westlake Chemical Gets Boost from Analysts with New Targets

Updated Category News Views 67

Westlake Chemical Upgraded to Neutral Recently, BofA Securities made a notable adjustment regarding Westlake Chemical (NASDAQ: WLK), changing the stock's rating from Underperform to Neutral. This upgrade included raising the price target to $159 from $151, reflecting a more balanced view on the company's trajectory. The changes stem from a reassessment that weighs current...

Continue Reading
Envision Energy Recognized Among Leading Climate Tech Innovators

Updated Category News Views 209

Envision Energy's Recognition in Climate Technology Envision Energy has earned a well-deserved place on a prestigious list recognizing transformative companies in climate technology. This acknowledgment highlights their significant contributions in the fight against climate change through innovative renewable energy solutions. A Global Leader in Renewable Energy Known for...

Continue Reading
Exploring Franco-Nevada's Ten-Year Investment Journey

Updated Category News Views 155

Understanding Franco-Nevada's Investment Growth Franco-Nevada (NYSE: FNV) has showcased impressive performance over the last decade, delivering an average annual return of 14.64%. With a market capitalization of $30.52 billion, it has consistently outperformed the overall market by 3.21% on an annualized basis. The Impact of Compounding Returns Let's say an investor...

Continue Reading